https://psychedelicspotlight.com/wp-content/uploads/2024/01/new-images-PS-1200-×-802-px-2024-01-03T153622.941.png 802 1200 Phil Dubley https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Phil Dubley2024-01-03 20:45:272024-01-04 21:57:30Efficacy of Ketamine for Depression and Other Mental Health Conditions: Top 10 Studies of 2023
55.4% of patients in the ketamine group exhibited a significant reduction in depressive symptoms. In comparison, 41.2% of patients undergoing ECT showed similar improvement.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/new-images-PS-1200-×-802-px-2023-12-22T130748.707.png 802 1200 Maria Holyanova https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Maria Holyanova2023-12-22 18:13:042023-12-22 18:54:25The Biggest Psychedelic News This Week: December 18 – 22
While yet another study shows psilocybin's efficacy in treating depression in cancer patients, and 2024 presidential candidates push for a psychedelics reform from all sides, Colorado public health officials fight over manure.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/new-images-PS-1200-×-802-px-2023-12-15T102351.736.png 802 1200 Maria Holyanova https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Maria Holyanova2023-12-15 16:09:002023-12-15 16:09:02The Biggest Psychedelic News This Week: December 11 – 15
As MDMA nears FDA approval, LSD's efficacy in treating generalized anxiety disorder is demonstrated in MindMed's Phase 2b study. Meanwhile, Congress has approved a psychedelic treatment bill for active duty service members suffering from PTSD.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/psilocybin-doses-depression.jpg 802 1200 Elena Schmidt https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Elena Schmidt2023-12-13 21:15:402023-12-16 16:44:1910 Key 2023 Psychedelic Studies Reveal Optimal Psilocybin Doses for Depression
2023 psychedelic research shows optimal psilocybin dose for depression and the efficacy of psilocybin to treat depression.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/new-images-PS-1200-×-802-px-2023-12-13T105218.526.png 802 1200 Maria Holyanova https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Maria Holyanova2023-12-13 16:47:202024-01-18 20:26:15MDMA-Assisted Therapy for PTSD Edges Toward Acceptance – When Might It Be Approved?
The FDA will have 60 days "to determine whether the MDMA-AT NDA application will be accepted for review and whether it will be a priority or standard review. The estimate timeline is six months or ten months.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/fO2jujB2tqupSt0knhCI-1-ws45k.jpg 832 1216 Phil Dubley https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Phil Dubley2023-12-07 18:59:032023-12-07 23:15:22Why Do We Feel Like We Can Score 40/20 in Visual Acuity on Low Doses of Psychedelics?
One possible reason for this phenomenon is psilocybin’s interaction with the thalamus, the section of our brain that receives sensory information and relays it to different brain areas for processing.
https://psychedelicspotlight.com/wp-content/uploads/2023/12/new-images-PS-1200-×-802-px-2023-12-01T113116.878.png 802 1200 Maria Holyanova https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Maria Holyanova2023-12-01 17:09:432023-12-01 17:42:20The Biggest Psychedelic News This Week: November 27th – December 1st
The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.
https://psychedelicspotlight.com/wp-content/uploads/2023/11/new-images-PS-1200-×-802-px-83.png 802 1200 Elena Schmidt https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Elena Schmidt2023-11-29 19:59:332023-12-01 16:55:16New Study Says LSD and Psilocybin Could Outperform Opioids for Pain, Without Developing Tolerance
Classic psychedelics might effectively kill pain with even greater vigor over time, sharply contrasting with opioids.
https://psychedelicspotlight.com/wp-content/uploads/2023/11/new-images-PS-1200-×-802-px-2023-11-24T123450.779.png 802 1200 Maria Holyanova https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Maria Holyanova2023-11-24 18:12:222023-11-24 18:12:25The Biggest Psychedelic News This Week: November 20th-24th
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach to treating ADHD.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.